<DOC>
	<DOCNO>NCT00486538</DOCNO>
	<brief_summary>This study design determine clinical efficacy toxicity ABT 869 treatment subject advance renal cell carcinoma previously receive treatment sunitinib .</brief_summary>
	<brief_title>Study ABT-869 Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Inclusion Criteria Subject undergone previous nephrectomy . Subject receive least 2 cycle ( 12 week ) treatment sunitinib RCC stop therapy due progressive disease within 100 day prior screen . Subject measurable disease , define least 1 unidimensionally measurable lesion CT scan define RECIST . ECOG Performance Score 01 . No history another active cancer within past 5 years.Life expectancy least 4 month . Willing take adequate measure prevent pregnancy . Exclusion Criteria Subject receive anticancer therapy within 21 day within period define 5 half life , whichever short , prior study drug administration . Subject untreated brain meningeal metastasis . Subject receive tyrosine kinase inhibitor ( TKI ) sunitinib sorafenib . Prior use Avastin allow . The subject receive therapeutic anticoagulation therapy . The subject history of/or currently exhibit clinically significant cancer relate event bleed ( e.g. , hematuria , hemoptysis ) . The subject currently exhibit symptomatic persistent , uncontrolled hypertension define diastolic blood pressure ( BP ) &gt; 100 mmHg ; systolic blood pressure ( BP ) &gt; 150 mmHg . The subject history myocardial infarction within 6 month Study Day 1 . The subject document leave ventricular ( LV ) Ejection Fraction &lt; 50 % . The subject know autoimmune disease renal involvement ( eg , Lupus ) . Female subject pregnant breast feeding . Subject receive antiretroviral therapy HIV . Subject clinically significant uncontrolled condition ( ) include limited : active uncontrolled infection , Class III IV heart failure define New York Heart Association functional classification system , unstable angina pectoris cardiac arrhythmia , history adrenal insufficiency , psychiatric illness/social situation would limit compliance study requirement ; Active , ulcerative colitis , Crohn 's disease , celiadisease condition interfere absorption . Subject medical condition , opinion study investigator place unacceptably high risk toxicity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>